The Biden administration has determined that it has the authority to seize patents of high-priced medicines, potentially opening the door to a more aggressive campaign to reduce drug prices.
This is being described as the “non-democrat approach” to increasing federal power without Congress’ involvement.
Although the administration will not widely use these rights, the Commerce Department plans to issue a new framework for federal agencies to consider march-in action against expensive drugs or products developed with federal help.
This move is part of Biden’s efforts to lower drug prices and boost competition in the industry. (Trending: Biden Bank Records Reveal Another Massive Bombshell)
According to Politico, “Biden officials now plan to make a fresh push to put health care at the center of Biden’s reelection platform, rolling out proposals in the coming days that would expand on Democrats’ passage of laws capping insulin prices for Medicare recipients and allowing Medicare to negotiate the price of certain drugs.”
“Biden has also portrayed himself as a chief antagonist of the pharmaceutical industry, casting his drug price policies as central to his administration’s battle against “Big Pharma,” continued the outlet.
The decision follows criticism from progressives over the administration’s reluctance to use march-in rights, and it comes as Biden seeks to emphasize his health agenda and portray himself as a challenger to the pharmaceutical industry.